?

?CCMO-48 | USP/EP-Certified Pharmaceutical Intermediate for Oncology & Research?

?Key Features?

• ?Ultra-High Purity?

  : ≥99.5% HPLC/GC-MS verified, compliant with 

  ?USP/EP pharmacopeial standards?

   for oncology drug development and API synthesis?14.

• ?Dual Applications?

  :

• ?Oncology Therapeutics?

  : Critical intermediate for 

  ?PARP inhibitor APIs?

   targeting breast, ovarian, and prostate cancers?46.

• ?Research Use?

  : Supports 

  ?preclinical studies?

   in DNA repair mechanisms and chemotherapy resistance?23.

• ?Stability?

  : 24-month shelf life under -20°C storage in nitrogen-sealed amber vials?35.

?Applications?

• ?API Manufacturing?

  : Enables scalable synthesis of 

  ?PARP inhibitor drugs?

   (e.g., Olaparib analogs)?46.

• ?Academic & Industrial R&D?

  : Used in 

  ?cancer biomarker studies?

   and 

  ?targeted therapy optimization?

  ?25.

?Quality Assurance?

• ?Regulatory Compliance?

  : Meets 

  ?residual solvent (<20 ppm)?

   and 

  ?genotoxic impurity (<0.1%)?

   limits per 

  ?ICH Q3 guidelines?

  ?35.

• ?Customization?

  : Available in 

  ?1g-10kg batches?

   with optional 

  ?COA/MSDS documentation?

  ?14.

?Google Keywords?:

• Bulk CCMO-48 Supplier USP/EP

• Oncology Intermediate API Synthesis

• PARP Inhibitor Raw Material

• *Pharmaceutical-Grade CCMO-48 99.5%*?12.